Skip to content
value.today

Imbria Pharmaceuticals, Inc.

Total raised
$148 M
3 rounds on record
Latest round
$67 M
Mar 2025
First round on record
Jul 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Imbria Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$67 MNo. 3$50 to $250 million

Imbria Pharmaceuticals, Inc.: Raise no. 3, Mar 2025

Investors in this round

10 investors had bought by the notice of Dec 16, 2025: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$67 M of $144 M offered; $78 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alvin Shih · Executive Officer, Director
  • Komal Joshi · Executive Officer
  • Andrew Levin · Director
  • Charles Dunn · Director
  • Ken Horne · Director
  • Luse Rebecca · Director
  • Pavan Cheruvu · Director
  • Zina Affas Besse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Komal Joshi, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Dec 16, 2025. Read the notice at the SEC.

equitySEC
Jun 2020$41 MNo. 2$10 to $50 million

Imbria Pharmaceuticals, Inc.: Raise no. 2, Jun 2020

Investors in this round

4 investors had bought by the notice of Jul 2, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$41 M of $81 M offered; $40 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David-Alexandre C. Gros · Executive Officer
  • Andrew C. Levin · Director
  • James C. Januzzi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David-Alexandre C. Gros, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 2, 2020. Read the notice at the SEC.

equitySEC
Jul 2018$40 MNo. 1$10 to $50 million

Imbria Pharmaceuticals, Inc.: Raise no. 1, Jul 2018

Investors in this round

3 investors had bought by the notice of Jul 9, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David-Alexandre C. Gros · Executive Officer, Director
  • Andrew C. Levin · Director
  • Pieter C. Boelhouwer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David-Alexandre C. Gros, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 9, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Imbria Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2025

That is all the official record says: Imbria Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Imbria Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Imbria Pharmaceuticals, Inc.
NameRoleNamed in
Alvin ShihExecutive officerDec 2025
Komal JoshiExecutive officerDec 2025
David-Alexandre C. GrosExecutive officerJul 2020
Alvin ShihDirectorDec 2025
Andrew LevinDirectorDec 2025
Charles DunnDirectorDec 2025
Ken HorneDirectorDec 2025
Luse RebeccaDirectorDec 2025
Pavan CheruvuDirectorDec 2025
Zina Affas BesseDirectorDec 2025
James JanuzziDirectorApr 2025
Rebecca LuseDirectorApr 2025
Andrew C. LevinDirectorJul 2020
James C. JanuzziDirectorJul 2020
David-Alexandre C. GrosDirectorJul 2018
Pieter C. BoelhouwerDirectorJul 2018